Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies

Breast Cancer Research and Treatment

Volumn 134, Issue 2, 2012, Pages 583-593

  Chen, Albert C ^a   Migliaccio, Ilenia ^a,b   Rimawi, Mothaffar ^a   Lopez Tarruella, Sara ^c   Creighton, Chad J ^a   Massarweh, Suleiman ^d   Huang, Catherine ^a   Wang, Yen Chao ^a   Batra, Surinder K ^e   Gutierrez, M Carolina ^a   Kent Osborne, C ^a   Schiff, Rachel ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ISTITUTO TOSCANO TUMORI   (Italy)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d UNIVERSITY OF KENTUCKY   (United States)

^e UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Drug resistance; Endocrine therapy; HER2 therapy; Mucin4; Mucinated phenotype; Mucins

Indexed keywords

EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HEMATOXYLIN; LAPATINIB; MUCIN 4; PROGESTERONE RECEPTOR; TRASTUZUMAB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL STRAIN MCF 7; CONTROLLED STUDY; GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOLECULARLY TARGETED THERAPY; MOUSE; MUCIN 4 GENE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ESTROGEN ANTAGONISTS; FEMALE; GENE EXPRESSION; HUMANS; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; MUCIN-4; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC; TAMOXIFEN; TRANSCRIPTOME; TUMOR BURDEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84868206699     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-012-2082-9     Document Type: Article

References (55)

1. Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, De Placido S, Osborne CK, Schiff R (2007) Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99(9):694-705. doi:10.1093/jnci/djk151
2. Arpino G, Wiechmann L, Osborne CK, Schiff R (2008) Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29(2):217-233. doi:10.1210/er.2006-0045
3. Massarweh S, Osborne CK, Creighton CJ, Qin L, Tsimelzon A, Huang S, Weiss H, Rimawi M, Schiff R (2008) Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res 68(3):826-833. doi:10.1158/0008-5472. CAN-07-2707
4. Britton DJ, Hutcheson IR, Knowlden JM, Barrow D, Giles M, McClelland RA, Gee JM, Nicholson RI (2006) Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth. Breast Cancer Res Treat 96(2):131-146. doi:10.1007/s10549-005-9070-2
5. Knowlden JM, Hutcheson IR, Jones HE, Madden T, Gee JM, Harper ME, Barrow D, Wakeling AE, Nicholson RI (2003) Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144(3):1032-1044
6. Leary AF, Drury S, Detre S, Pancholi S, Lykkesfeldt AE, Martin LA, Dowsett M, Johnston SR (2010) Lapatinib restores hormone sensitivity with differential effects on estrogen receptor signaling in cell models of human epidermal growth factor receptor 2-negative breast cancer with acquired endocrine resistance. Clin Cancer Res 16(5):1486-1497. doi:10.1158/1078-0432. CCR-09-1764
7. Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Janicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1-and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19(18):3808-3816
8. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M (2009) Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 27(33):5538-5546. doi:10.1200/JCO.2009.23.3734
9. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Revil C, Jones A (2009) Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27(33):5529-5537. doi:10.1200/JCO.2008.20.6847
10. Osborne CK, Neven P, Dirix LY, Mackey JR, Robert J, Underhill C, Schiff R, Gutierrez C, Migliaccio I, Anagnostou VK, Rimm DL, Magill P, Sellers M (2011) Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study. Clin Cancer Res 17(5):1147-1159. doi:10.1158/1078-0432. CCR-10-1869
11. Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R (2006) Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer. Cancer Res 66(16):8266-8273. doi:10.1158/0008-5472. CAN-05-4045
12. Rimawi MF, Wiechmann LS, Wang YC, Huang C, Migliaccio I, Wu MF, Gutierrez C, Hilsenbeck SG, Arpino G, Massarweh S, Ward R, Soliz R, Osborne CK, Schiff R (2011) Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER-2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 17:1351-1361
13. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, Shepard HM, Osborne CK (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24(2):85-95
14. Moniaux N, Varshney GC, Chauhan SC, Copin MC, Jain M, Wittel UA, Andrianifahanana M, Aubert JP, Batra SK (2004) Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J Histochem Cytochem 52(2):253-261
15. Creighton CJ, Massarweh S, Huang S, Tsimelzon A, Hilsenbeck SG, Osborne CK, Shou J, Malorni L, Schiff R (2008) Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts. Cancer Res 68(18):7493-7501. doi:10.1158/0008-5472. CAN-08-1404
16. Saldanha AJ (2004) Java Treeview-extensible visualization of microarray data. Bioinformatics 20(17):3246-3248. doi:10.1093/bioinformatics/bth349bth349
17. Hammerich-Hille S, Kaipparettu BA, Tsimelzon A, Creighton CJ, Jiang S, Polo JM, Melnick A, Meyer R, Oesterreich S (2010) SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. J Biol Chem 285(6):3608-3616. doi:10.1074/jbc. M109.066431
18. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) method. Methods 25 (4):402-408. doi:10.1006/meth. 2001.1262
19. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM (2006) Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5(10):2512-2521. doi:10.1158/1535-7163. MCT-06-0334
20. Shapiro SS, Wilk MB (1965) An analysis of variance test for normality (complete samples). Biometrika 52(3-4):591-611
21. Mann HB, Whitney DR (1947) On a test of whether one of two random variables is stochastically larger than the other. Ann Math Stat 18(1):50-60
22. Team RDC (2010) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna
23. Steinbrecher JS, Silverberg SG (1976) Signet-ring cell carcinoma of the breast. The mucinous variant of infiltrating lobular carcinoma? Cancer 37(2):828-840
24. Chaturvedi P, Singh AP, Chakraborty S, Chauhan SC, Bafna S, Meza JL, Singh PK, Hollingsworth MA, Mehta PP, Batra SK (2008) MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells. Cancer Res 68(7):2065-2070. doi:10.1158/0008-5472. CAN-07-6041
25. Carraway KL, Perez A, Idris N, Jepson S, Arango M, Komatsu M, Haq B, Price-Schiavi SA, Zhang J, Carraway CA (2002) Muc4/sialomucin complex, the intramembrane ErbB2 ligand, in cancer and epithelia: to protect and to survive. Prog Nucleic Acid Res Mol Biol 71:149-185
26. Hollingsworth MA, Swanson BJ (2004) Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 4(1):45-60. doi:10.1038/ nrc1251nrc1251
27. Karg A, Dinc ZA, Basok O, Ucvet A (2006) MUC4 expression and its relation to ErbB2 expression, apoptosis, proliferation, differentiation, and tumor stage in non-small cell lung cancer (NSCLC). Pathol Res Pract 202(8):577-583. doi:10.1016/j.prp. 2006.04.002
28. Kwon KY, Ro JY, Singhal N, Killen DE, Sienko A, Allen TC, Zander DS, Barrios R, Haque A, Cagle PT (2007) MUC4 expression in non-small cell lung carcinomas: relationship to tumor histology and patient survival. Arch Pathol Lab Med 131(4):593-598
29. Tamada S, Shibahara H, Higashi M, Goto M, Batra SK, Imai K, Yonezawa S (2006) MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin Cancer Res 12(14 Pt 1):4257-4264. doi:10.1158/1078-0432. CCR-05-2814
30. Tsutsumida H, Goto M, Kitajima S, Kubota I, Hirotsu Y, Wakimoto J, Batra SK, Imai K, Yonezawa S (2007) MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. Lung Cancer 55(2):195-203. doi:10.1016/j. lungcan. 2006.10.013
31. Chauhan SC, Singh AP, Ruiz F, Johansson SL, Jain M, Smith LM, Moniaux N, Batra SK (2006) Aberrant expression of MUC4 in ovarian carcinoma: diagnostic significance alone and in combination with MUC1 and MUC16(≥A125). Mod Pathol 19 (10):1386-1394. doi:10.1038/modpathol.3800646
32. Munro EG, Jain M, Oliva E, Kamal N, Lele SM, Lynch MP, Guo L, Fu K, Sharma P, Remmenga S, Growdon WB, Davis JS, Rueda BR, Batra SK (2009) Upregulation of MUC4 in cervical squamous cell carcinoma: pathologic significance. Int J Gynecol Pathol 28(2):127-133. doi:10.1097/PGP. 0b013e318184f3e0
33. Singh AP, Chauhan SC, Bafna S, Johansson SL, Smith LM, Moniaux N, Lin MF, Batra SK (2006) Aberrant expression of transmembrane mucins, MUC1 and MUC4, in human prostate carcinomas. Prostate 66(4):421-429. doi:10.1002/pros.20372
34. Miyahara N, Shoda J, Ishige K, Kawamoto T, Ueda T, Taki R, Ohkohchi N, Hyodo I, Thomas MB, Krishnamurthy S, Carraway KL, Irimura T (2008) MUC4 interacts with ErbB2 in human gallbladder carcinoma: potential pathobiological implications. Eur J Cancer 44(7):1048-1056. doi:10.1016/j.ejca.2008.03.007
35. Andrianifahanana M, Moniaux N, Schmied BM, Ringel J, Friess H, Hollingsworth MA, Buchler MW, Aubert JP, Batra SK (2001) Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res 7(12):4033-4040
36. Workman HC, Miller JK, Ingalla EQ, Kaur RP, Yamamoto DI, Beckett LA, Young LJ, Cardiff RD, Borowsky AD, Carraway KL, Sweeney C, Carraway KL 3rd (2009) The membrane mucin MUC4 is elevated in breast tumor lymph node metastases relative to matched primary tumors and confers aggressive properties to breast cancer cells. Breast Cancer Res 11(5):R70. doi:10.1186/bcr2364
37. Workman HC, Sweeney C, Carraway KL 3rd (2009) The membrane mucin Muc4 inhibits apoptosis induced by multiple insults via ErbB2-dependent and ErbB2-independent mechanisms. Cancer Res 69(7):2845-2852. doi:10.1158/0008-5472. CAN-08-2089
38. Ramsauer VP, Pino V, Farooq A, Carothers Carraway CA, Salas PJ, Carraway KL (2006) Muc4-ErbB2 complex formation and signaling in polarized CACO-2 epithelial cells indicate that Muc4 acts as an unorthodox ligand for ErbB2. Mol Biol Cell 17(7):2931-2941. doi:10.1091/mbc. E05-09-0895
39. Yokoyama A, Shi BH, Kawai T, Konishi H, Andoh R, Tachikawa H, Ihara S, Fukui Y (2007) Muc4 is required for activation of ErbB2 in signet ring carcinoma cell lines. Biochem Biophys Res Commun 355(1):200-203. doi:10.1016/j.bbrc.2007. 01.133
40. Carraway KL 3rd, Rossi EA, Komatsu M, Price-Schiavi SA, Huang D, Guy PM, Carvajal ME, Fregien N, Carraway CA, Carraway KL (1999) An intramembrane modulator of the ErbB2 receptor tyrosine kinase that potentiates neuregulin signaling. J Biol Chem 274(9):5263-5266
41. Funes M, Miller JK, Lai C, Carraway KL 3rd, Sweeney C (2006) The mucin Muc4 potentiates neuregulin signaling by increasing the cell-surface populations of ErbB2 and ErbB3. J Biol Chem 281(28):19310-19319. doi:10.1074/jbc. M603225200
42. Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65(2):473-482
43. Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL (2002) Rat Muc4(sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 99 (6):783-791. doi:10.1002/ijc.10410
44. Mejias-Luque R, Peiro S, Vincent A, Van Seuningen I, De Bolos C (2008) IL-6 induces MUC4 expression through gp130/STAT3 pathway in gastric cancer cell lines. Biochim Biophys Acta 1783(10):1728-1736. doi:10.1016/j.bbamcr.2008.05.020
45. Andrianifahanana M, Singh AP, Nemos C, Ponnusamy MP, Moniaux N, Mehta PP, Varshney GC, Batra SK (2007) IFN-gamma-induced expression of MUC4 in pancreatic cancer cells is mediated by STAT-1 upregulation: a novel mechanism for IFN-gamma response. Oncogene 26(51):7251-7261. doi:10.1038/sj. onc.1210532
46. Andrianifahanana M, Agrawal A, Singh AP, Moniaux N, Van Seuningen I, Aubert JP, Meza J, Batra SK (2005) Synergistic induction of the MUC4 mucin gene by interferon-gamma and retinoic acid in human pancreatic tumour cells involves a reprogramming of signalling pathways. Oncogene 24(40):6143-6154. doi:10.1038/sj.onc.1208756
47. Damera G, Xia B, Ancha HR, Sachdev GP (2006) IL-9 modulated MUC4 gene and glycoprotein expression in airway epithelial cells. Biosci Rep 26(1):55-67. doi:10.1007/s10540-006-9000-5
48. Damera G, Xia B, Sachdev GP (2006) IL-4 induced MUC4 enhancement in respiratory epithelial cells in vitro is mediated through JAK-3 selective signaling. Respir Res 7:39. doi:10.1186/1465-9921-7-39
49. Perez A, Barco R, Fernandez I, Price-Schiavi SA, Carraway KL (2003) PEA3 transactivates the Muc4/sialomucin complex promoterinmammary epithelial and tumor cells. JBiol Chem 278(38):36942-36952. doi:10.1074/jbc. M300264200M300264200
50. Guo S, Sonenshein GE (2004) Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway. Mol Cell Biol 24(19):8681-8690. doi:10.1128/MCB.24.19.8681-8690.200424/19/8681
51. Creighton CJ, Fu X, Hennessy BT, Casa AJ, Zhang Y, Gonzalez-Angulo AM, Lluch A, Gray JW, Brown PH, Hilsenbeck SG, Osborne CK, Mills GB, Lee AV, Schiff R (2010) Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER? breast cancer. Breast Cancer Res 12(3):R40. doi:10.1186/bcr2594
52. Moniaux N, Chaturvedi P, Varshney GC, Meza JL, Rodriguez-Sierra JF, Aubert JP, Batra SK (2007) Human MUC4 mucin induces ultra-structural changes and tumorigenicity in pancreatic cancer cells. Br J Cancer 97(3):345-357. doi:10.1038/sj.bjc.66 03868
53. Ponnusamy MP, Singh AP, Jain M, Chakraborty S, Moniaux N, Batra SK (2008) MUC4 activates HER2 signalling and enhances the motility of human ovarian cancer cells. Br J Cancer 99(3):520-526. doi:10.1038/sj.bjc.6604517
54. Ponnusamy MP, Lakshmanan I, Jain M, Das S, Chakraborty S, Dey P, Batra SK (2010) MUC4 mucin-induced epithelial to mesenchymal transition: a novel mechanism for metastasis of human ovarian cancer cells. Oncogene. doi:10.1038/onc.2010.309
55. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R (2004) Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 96(12):926-935